Nanocapsules: A Novel Lipid Formulation Platform for Platinum-based Anti-cancer Drugs

References

• Akaboshi M., Kawai K., Maki H., Akuta K., Ujeno Y., Miyahara T. The number of platinum atoms binding to DNA, RNA, and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration. Jpn. J. Cancer. Res. 1992; 83: 522–526
   PubMedGoogle Scholar
• Andresen T. L., Jensen S. S., Jorgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog. Lipid. Res. 2005; 44: 68–97
   PubMed Web of Science ®Google Scholar
• Bandak S., Goren D., Horowitz A., Tzemach D., Gabizon A. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anti Canc. Drugs 1999; 10: 911–920
   PubMed Web of Science ®Google Scholar
• Bloemink M. J., Reedijk J. Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Met. Ions Biol. Syst. 1996; 32: 641–685
   PubMedGoogle Scholar
• Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol. Rep. 2004; 12: 3–12
   PubMed Web of Science ®Google Scholar
• Burger K. N., Staffhorst R. W., de Vijlder H. C., Velinova M. J., Bomans P. H., Frederik P. M., de Kruijff B. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat. Med. 2002; 8: 81–84
   PubMed Web of Science ®Google Scholar
• Chupin V., de Kroon A. I., de Kruijff B. Molecular architecture of nanocapsules, bilayer-enclosed solid particles of Cisplatin. J. Am. Chem. Soc. 2004; 126: 13816–13821
   PubMed Web of Science ®Google Scholar
• Connors T. A., Jones M., Ross W. C., Braddock P. D., Khokhar A. R., Tobe M. L. New platinum complexes with anti-tumour activity. Chem. Biol. Interact. 1972; 5: 415–424
   PubMed Web of Science ®Google Scholar
• Cooley M. E., Davis L. E., DeStefano M., Abrahm J. Cisplatin: a clinical review. Part I—Current uses of cisplatin and administration guidelines. Cancer Nurs. 1994; 17: 173–184
   PubMed Web of Science ®Google Scholar
• de Kroon A. I., Staffhorst R. W., de Kruijff B., Burger K. N. Cisplatin nanocapsules. Methods Enzymol. 2005; 391: 118–125
   PubMed Web of Science ®Google Scholar
• Dijt F. J., Fichtinger-Schepman A. M., Berends F., Reedijk J. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res. 1988; 48: 6058–6062
   PubMed Web of Science ®Google Scholar
• Douple E. B. cis-Diamminedichloroplatinum(II): effects of a representative metal coordination complex on mammalian cells. Pharmacol Ther. 1984; 25: 297–326
   PubMed Web of Science ®Google Scholar
• el-Khateeb M., Appleton T. G., Gahan L. R., Charles B. G., Berners-Price S. J., Bolton A. M. Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques. J. Inorg. Biochem. 1999; 77: 13–21
   PubMed Web of Science ®Google Scholar
• Hamelers I. H., van Loenen E., Staffhorst R. W., de Kruijff B., de Kroon A. I. Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin. Mol. Cancer Ther. 2006; 5: 2007–2012
   PubMed Web of Science ®Google Scholar
• Harrap K. R. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. 1985; 12(Suppl A)21–33
   PubMed Web of Science ®Google Scholar
• Harrington K. J., Lewanski C. R., Northcote A. D., Whittaker J., Wellbank H., Vile R. G., Peters A. M., Stewart J. S. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann. Oncol. 2001; 12: 493–496
   PubMed Web of Science ®Google Scholar
• Helleman J. H., Burger I. H., Hamelers A. W., Boersma A. I., de Kroon G., Stoter K., Nooter. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter. Cancer Biol. Ther. 2006; 5: 943–949
   PubMed Web of Science ®Google Scholar
• Knox R. J., Friedlos F., Lydall D. A., Roberts J. J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986; 46: 1972–1979
   PubMed Web of Science ®Google Scholar
• Ma J., Verweij J., Kolker H. J., van Ingen H. E., Stoter G., Schellens J. H. Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 and 20 h infusion. Br. J. Cancer. 1994; 69: 858–862
   PubMed Web of Science ®Google Scholar
• Meerum Terwogt J. M., Groenewegen G., Pluim D., Maliepaard M., Tibben M. M., Huisman A., ten Bokkel Huinink W. W., Schot M., Welbank H., Voest E. E., Beijnen J. H., Schellens J. M. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother. Pharmacol. 2002; 49: 201–210
   PubMed Web of Science ®Google Scholar
• Newman M. S., Colbern G. T., Working P. K., Engbers C., Amantea M. A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 1999; 43: 1–7
   PubMed Web of Science ®Google Scholar
• Papisov M. I. Theoretical considerations of RES-avoiding liposomes: Molecular mechanics and chemistry of liposome interactions. Adv. Drug Deliv. Rev. 1998; 32: 119–138
   PubMed Web of Science ®Google Scholar
• Peleg-Shulman T., Gibson D., Cohen R., Abra R., Barenholz Y. Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim. Biophys. Acta 2001; 1510: 278–291
   PubMed Web of Science ®Google Scholar
• Reedijk J. New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc. Natl. Acad. Sci. U S A. 2003; 100: 3611–3616
   PubMed Web of Science ®Google Scholar
• Riley C. M., Sternson L. A. Cisplatin. Analytical Profiles of Drug Substances, K. Florey. Academic Press, New York 1985; 14: 78–105
   Google Scholar
• Schellens J. H., Ma J., Planting A. S., van der Burg M. E., van Meerten E., de Boer-Dennert M., Schmitz P. I., Stoter G., Verweij J. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br. J. Cancer. 1996; 73: 1569–1575
   PubMed Web of Science ®Google Scholar
• Speelmans G., Sips W. H., Grisel R. J., Staffhorst R. W., Fichtinger-Schepman A. M., Reedijk J., de Kruijff B. The interaction of the anti-cancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride ion concentration. Biochim. Biophys. Acta. 1996; 1283: 60–66
   PubMed Web of Science ®Google Scholar
• Speelmans G., Staffhorst R. W., Versluis K., Reedijk J., de Kruijff B. Cisplatin complexes with phosphatidylserine in membranes. Biochemistry 1997; 36: 10545–10550
   PubMed Web of Science ®Google Scholar
• Stathopoulos G. P., Boulikas T., Vougiouka M., Deliconstantinos G., Rigatos S., Darli E., Viliotou V., Stathopoulos J. G. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol. Rep. 2005; 13: 589–595
   PubMed Web of Science ®Google Scholar
• Vail D. M., Kurzman I. D., Glawe P. C., O'Brien M. G., Chun R., Garrett L. D., Obradovich J. E., Fred R. M., 3rd, Khanna C., Colbern G. T., Working P. K. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother. Pharmacol. 2002; 50: 131–136
   PubMed Web of Science ®Google Scholar
• van der Vijgh W. J. Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet. 1991; 21: 242–261
   PubMed Web of Science ®Google Scholar
• Velinova M. J., Staffhorst R. W., Mulder W. J., Dries A. S., Jansen B. A., de Kruijff B., de Kroon A. I. Preparation and stability of lipid-coated nanocapsules of cisplatin: anionic phospholipid specificity. Biochim. Biophys. Acta 2004; 1663: 135–142
   PubMed Web of Science ®Google Scholar
• Wang D., Lippard S. J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005; 4: 307–320
   PubMed Web of Science ®Google Scholar
• Wernyj R. P., Morin P. J. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist. Updat. 2004; 7: 227–232
   PubMed Web of Science ®Google Scholar
• Xiao C., Qi X., Maitani Y., Nagai T. Sustained release of cisplatin from multivesicular liposomes: potentiation of antitumor efficacy against S180 murine carcinoma. J. Pharm. Sci. 2004; 93: 1718–1724
   PubMed Web of Science ®Google Scholar